

**ABSTRACT**

The invention relates to a novel therapeutic use of 14,15-dihydro-20,21-dinoreburnamenin-14-ol for the treatment of serious depression in humans, particularly  
5 for the treatment of a patients resistant to conventional anti-depressant treatments and for treatment of sleep/waking cycle disorders.